Ligand Pharmaceuticals (LGND) Interest & Investment Income (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 13 years of Interest & Investment Income data on file, last reported at $6.7 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income rose 275.78% year-over-year to $6.7 million; the trailing twelve-month figure through Mar 2026 stood at $18.5 million (up 137.55% YoY), and the FY2025 full-year result was $13.7 million, up 69.57% from the prior year.
• Interest & Investment Income climbed to $6.7 million in Q1 2026, from $6.4 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $6.7 million in Q1 2026 to a low of $134000.0 in Q1 2022.
• A 5-year average of $2.2 million and a median of $1.8 million in 2025 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income slumped 54.73% in 2022 and soared 970.9% in 2023, its largest moves.
• Tracing LGND's Interest & Investment Income over 5 years: stood at $1.0 million in 2022, then jumped by 65.49% to $1.7 million in 2023, then rose by 14.06% to $1.9 million in 2024, then surged by 231.07% to $6.4 million in 2025, then gained by 4.1% to $6.7 million in 2026.
• Business Quant data shows LGND's Interest & Investment Income at $6.7 million in Q1 2026, $6.4 million in Q4 2025, and $3.9 million in Q3 2025.